12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Heplisav regulatory update

Dynavax said FDA's Vaccines and Related Biological Products Advisory Committee will discuss a BLA for HBV product Heplisav at the committee's Nov. 14-15 meeting. Heplisav is under...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >